Gland Pharma Limited reports a change in its board or management
In short
Gland Pharma Limited informed the exchange that it appointed Mr Xiao Le as Chief Investment Officer for Gland Pharma International Pte. Ltd., its wholly owned subsidiary, effective November 9, 2026. In simple terms, the company has named a new investment chief for its overseas subsidiary. The appointment takes effect on November 9, 2026.
Why it matters
A change at the leadership or audit level — worth checking who's departing/joining and whether the filing gives a reason. This brief was written from the filing itself: at the time of writing, no publisher in our feed had covered it.